Advisory Committees

2010 Meeting Materials, Transmissible Spongiform Encephalopathies Advisory Committee

October 28-29, 2010

On October 28, 2010 the Committee will discuss: (1) FDA’s risk assessment for potential exposure to the variant Creutzfeldt - Jakob disease (vCJD) agent in U.S.-licensed plasma-derived Factor VIII and (2) labeling of blood and blood components and plasma-derived products, including plasma-derived albumin and products containing plasma-derived albumin, to address the possible risk of transmission of vCJD.

Page Last Updated: 08/13/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.